SNRIs for Bipolar II Disorder: Efficacy, Risks & Clinical Guidelines

Serotonin-norepinephrine reuptake inhibitors (SNRIs: venlafaxine, duloxetine, desvenlafaxine, levomilnacipran) are not first-line for bipolar II depression due to switch risk.

Current Guidelines (CANMAT/ISBD, APA)

• First-Line: Quetiapine, lurasidone, lamotrigine, lithium, valproate, cariprazine.
• Antidepressant Use: Only with concurrent mood stabilizer; avoid monotherapy. Bupropion preferred (lower switch risk). SSRIs/SNRIs second-line with caution.

SNRI-Specific Concerns

• Manic/Hypomanic Switch: Rate 2–5% with mood stabilizer; higher without. Venlafaxine > duloxetine.
• Rapid Cycling: Antidepressants may induce.
• Withdrawal Syndrome: Venlafaxine notorious (dizziness, "brain zaps," nausea). Taper slowly.

When SNRIs May Be Considered

• Bipolar II depression refractory to mood stabilizers + quetiapine/lurasidone.
• Comorbid anxiety (GAD, panic) where SNRIs have efficacy.
• Pain syndromes (fibromyalgia, neuropathic) where duloxetine is indicated.

Monitoring Requirements

• Mood tracking (daily rating scales).
• Weekly contact x 4 weeks after initiation/dose change.
• Screen for hypomania (DIGFAST: Decreased sleep, Inflated self-esteem, Grandiosity, Flight of ideas, Activity increase, Speech pressured, Thought racing).

Contraindications/Precautions

• Pregnancy/breastfeeding (limited data; paroxetine/sertraline preferred if needed).
• Uncontrolled hypertension (venlafaxine dose-dependent BP rise).
• Severe renal/hepatic impairment (dose adjust).
• Concurrent MAOI (14-day washout).

Psychiatrist supervision mandatory. Never self-medicate bipolar disorder.